Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation

The FDA granted this designation to inavolisib in combination with Ibrance (palbociclib) and Faslodex (fulvestrant) to treat adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. HR-positive breast cancer is the most prevalent type of breast cancer and roughly accounts for approximately 70% of cases. The d ...